Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O95163
UPID:
ELP1_HUMAN
Alternative names:
IkappaB kinase complex-associated protein; p150
Alternative UPACC:
O95163; Q5JSV2; Q9H327; Q9UG87
Background:
Elongator complex protein 1 (ELP1), also known as IkappaB kinase complex-associated protein or p150, plays a crucial role in the modification of tRNAs, essential for protein synthesis. It is involved in the formation of carboxymethyluridine in tRNA's wobble base, influencing neuron migration and branching in the cerebral cortex.
Therapeutic significance:
ELP1's mutation is linked to hereditary sensory and autonomic neuropathy 3, characterized by sensory and autonomic abnormalities, and to medulloblastoma, a pediatric brain tumor. Understanding ELP1's role could lead to novel treatments for these conditions.